ANIX — Anixa Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Anixa Biosciences Announces Maximum Tolerated Dose Reached In Trial Of Preventative Breast Cancer Vaccine
Brief: Anixa Biosciences Announces Commencement Of Phase 1B Trial Of Its Breast Cancer Vaccine
Brief: Anixa Biosciences Inc Files For Mixed Shelf Of Up To $200 Mln
Brief: Anixa Biosciences announces treatment of first patient in its Ovarian Cancer Car-T Clinical Trial
Brief: Anixa Biosciences Announces Notice Of Allowance Of Additional Patent On Breast Cancer Vaccine Technology
Brief: Anixa Biosciences Says Promoted Current Chief Operating Officer And CFO, To President Effective Immediately
Brief: Anixa Biosciences Announces Japanese Patent On Ovarian Cancer Vaccine
Brief: Anixa Biosciences And MolGenie Announce Early Potency Analysis Of SARS-CoV-2 Protease Inhibitor
U.S. STOCKS ON THE MOVE-Xilinx, Stryve Foods, Nutriband
U.S. STOCKS ON THE MOVE-Helbiz, Global Industrial, Stitch Fix, Intel
U.S. STOCKS ON THE MOVE-Bumble, U.S. banks, Mimecast, crypto stocks, Palantir, Etsy
Anixa Bio says COVID-19 compounds may work against Omicron, shares rise
Brief: Anixa Biosciences And Molgenie Announce That Their CoOVID-19 Compounds Are Expected To Be Effective Against The Omicron Variant
Brief: Anixa Biosciences Announces Patient Dosing Of Its Investigational Vaccine Candidate In A First-Of-Its-Kind Preventative Breast Cancer Vaccine Study
Brief: Anixa Biosciences Announces First Chinese Patent On Its Car-T Cancer Therapy Technology
Brief: Anixa Biosciences Announces Notice Of Allowance For Additional Patent On Its CAR-T Cancer Therapy
Brief: Anixa Biosciences Appoints Pamela Garzone As Chief Development Officer
Anixa Biosciences Inc reports results for the quarter ended in July - Earnings Summary
Brief: Anixa Biosciences Gets FDA Clearance For Ovarian Cancer Trial